Clinical Trials Browser

Phase 1/2 × Interventional × Solid Tumor × Clear all

NCT07229638 2026-03-12

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07466160 2026-03-12

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04939610 2026-03-11

LuMIERE

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07069062 2026-03-09

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06667960 2026-03-05

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07392736 2026-02-06

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07382531 2026-02-04

OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05262530 2026-01-21

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Phase 1/2 Terminated

Other solid neoplasm

Solid Tumor

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06631079 2026-01-08

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT04175847 2026-01-07

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor

NCT05174585 2026-01-06

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor

NCT06198426 2025-12-30

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Other solid neoplasm

Solid Tumor

NCT06712680 2025-12-23

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07229586 2025-12-19

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07258121 2025-12-02

Study of ZGGS34 in Participants With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05991349 2025-11-25

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor

NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT06212076 2025-09-24

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Phase 1/2 Completed

37 enrolled 32 charts

Other solid neoplasm

Solid Tumor

NCT06468358 2025-09-11

TRIGGERCD8

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT02992210 2025-09-08

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04455620 2025-07-02

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Phase 1/2 Terminated

49 enrolled 19 charts

Other solid neoplasm

Solid Tumor

NCT06603844 2025-06-03

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05982522 2025-04-30

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT06949761 2025-04-29

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

Other solid neoplasmThoracic

Solid Tumor

NCT05379946 2025-04-08

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05729399 2025-02-17

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT03707808 2025-01-20

myDAvIpNi

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06150885 2024-12-03

CAR001

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06117566 2024-11-25

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT03592264 2024-10-15

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Phase 1/2 Terminated

GastrointestinalOther solid neoplasm

Solid Tumor

NCT06239298 2024-06-14

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06237413 2024-03-06

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04984668 2024-02-09

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT05576961 2024-01-23

Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT05923008 2023-11-29

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT03834948 2023-08-22

AO-176 in Multiple Solid Tumor Malignancies

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor

NCT05934539 2023-07-07

ALG.APV-527 First-in-human Study

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT05909436 2023-06-18

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05869240 2023-06-06

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT05207787 2023-06-01

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Phase 1/2 Unknown

LymphoidOther solid neoplasm

Solid Tumor

NCT05748938 2023-03-01

A Study of RD14-01 in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT05437315 2022-06-29

GD2/PSMA Bi-specific CAR-T Cell Therapy

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05165849 2022-05-20

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT04432649 2020-06-16

Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumor

NCT02541604 2020-02-25

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Phase 1/2 Terminated

87 enrolled 41 charts

Other solid neoplasm

Solid Tumor